- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: lipodystrophy.
Displaying page 1 of 2.
EudraCT Number: 2007-003233-16 | Sponsor Protocol Number: TH9507-CTR-1012 | Start Date*: 2007-09-19 | |||||||||||
Sponsor Name:Theratechnologies Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Su... | |||||||||||||
Medical condition: HIV-associated lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000493-35 | Sponsor Protocol Number: ISIS-304801-CS17 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:Akcea Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy | |||||||||||||
Medical condition: Partial lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005444-88 | Sponsor Protocol Number: TH9507-CTR-1011 | Start Date*: 2007-01-16 | |||||||||||
Sponsor Name:Theratechnologies Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess A... | |||||||||||||
Medical condition: HIV-associated lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000138-33 | Sponsor Protocol Number: R4461-PLD-20100 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy | |||||||||||||
Medical condition: Familial Partial Lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003951-54 | Sponsor Protocol Number: MWD08 | Start Date*: 2010-01-05 | |||||||||||
Sponsor Name:Charité University Medicine Berlin | |||||||||||||
Full Title: Intraveneous induction theraphy followed by oral theraphy against exclusive oral theraphy: randomized trial for the treatment of Whipple's disease | |||||||||||||
Medical condition: ICD 10 K90.8 Sonstige intestinale Malabsorption - Whipple disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004665-42 | Sponsor Protocol Number: ST 200 DS 05-002 | Start Date*: 2006-03-17 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Evaluation of the efficacy and tollerability of long-term somministration of Acetyl-l-carnitine in the treatment of HIV related lipodystrophy.Parallel group, randomized, double blind, controlled ve... | |||||||||||||
Medical condition: HIV related LIPODYSTROPHY. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004846-25 | Sponsor Protocol Number: Pfizer-Prevenar13-2015 | Start Date*: 2016-07-15 |
Sponsor Name:Maastricht University | ||
Full Title: Immunization against oxLDL in patients with lysosomal lipid diseases and associated metabolic disorders | ||
Medical condition: Familial hypercholesterolemia Niemann-Pick disease type B (NPB) Niemann-Pick disease type C (NPC) Partial lipodystrophy in children and adults | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003014-22 | Sponsor Protocol Number: Thalamus_V3 | Start Date*: 2018-06-25 |
Sponsor Name:Medical University of Vienna | ||
Full Title: The role of leptin in regulating hepatic lipid metabolism in humans | ||
Medical condition: lipodystrophy patients, patients after liver transplantation and healthy controls | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002740-10 | Sponsor Protocol Number: AI424-131 | Start Date*: 2005-05-12 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, vers... | ||
Medical condition: HIV-infected individuals with lipodystrophy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004539-57 | Sponsor Protocol Number: Dio/01/2013 | Start Date*: 2014-01-30 | ||||||||||||||||
Sponsor Name:ALIO MEDICA Sp. z o.o. | ||||||||||||||||||
Full Title: A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleang... | ||||||||||||||||||
Medical condition: lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005672-33 | Sponsor Protocol Number: PR-0095_01 | Start Date*: 2006-07-26 |
Sponsor Name:IATEC B.V. | ||
Full Title: A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens ve... | ||
Medical condition: HIV-1 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Ongoing) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004021-26 | Sponsor Protocol Number: RRK 2768 | Start Date*: 2005-10-06 |
Sponsor Name:University Hospital Birmingham | ||
Full Title: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic reg... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003797-25 | Sponsor Protocol Number: GH100-013 | Start Date*: 2005-12-09 |
Sponsor Name:ConjuChem, Inc. | ||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Visc... | ||
Medical condition: Patients 18 to 65 years old with HIV-associated visceral obesity, on a stable antiviral regimen for at least 6 weeks, with a viral load ≤1,000 copies/mL and CD4 count ≥200 cells/mm3, a body mass in... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001476-37 | Sponsor Protocol Number: PENTA17 | Start Date*: 2015-12-16 | |||||||||||
Sponsor Name:Fondazione PENTA ONLUS | |||||||||||||
Full Title: SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety ... | |||||||||||||
Medical condition: Paediatric HIV-1 Infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) GB (GB - no longer in EU/EEA) BE (Completed) DE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004653-14 | Sponsor Protocol Number: UoL000097 | Start Date*: 2015-04-17 |
Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | ||
Full Title: A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE) | ||
Medical condition: Metastatic pancreatic carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014316-35 | Sponsor Protocol Number: 576/09 | Start Date*: 2009-08-26 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Phase IIb pilot study for the evaluation of the safety and the feasibility of treatment simplification to tenofovir+emtricitabina+raltegravir or to lamivudine+abacavir+raltegravir in patients with ... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011816-39 | Sponsor Protocol Number: | Start Date*: 2010-01-21 |
Sponsor Name:Imperial College London | ||
Full Title: A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects. ‘The First Failure Study’ : ‘FAST’ | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-016090-14 | Sponsor Protocol Number: HCSKAL-2009-01 | Start Date*: 2009-12-16 | |||||||||||
Sponsor Name:Dr. Vicente Estrada | |||||||||||||
Full Title: Análisis de los cambios en el tejido adiposo de pacientes con infección VIH y lipoatrofia en tratamiento con análogos de nucleósidos timidínicos, tras el cambio a monoterapia con Lopinavir/ritonavir | |||||||||||||
Medical condition: Pacientes infectados con ViH-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2025-000001-16 | Sponsor Protocol Number: I4V-JE-JAJE | Start Date*: 2025-02-19 | |||||||||||||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||
Full Title: A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients with NNS/CANDLE, SAVI, and AGS | |||||||||||||||||||||||
Medical condition: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Sy... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001635-23 | Sponsor Protocol Number: TMC114IFD3003 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:Janssen Cilag International N.V. | |||||||||||||
Full Title: PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IE (Completed) DE (Completed) ES (Completed) AT (Completed) HU (Completed) DK (Completed) IT (Completed) SE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
